However, despite the treatment the prevalence of elevated PCh functionality in sympathetically mediated diseases is still high - e.g. in HF patients PCh oversensitivity can be identified in more than every third patient despite guidelines-recommended treatment including beta-blockers and renin-angiotensin-aldosterone axis modulators (Niewinski et al., 2013). The gene discussed is REN; the disease is hydrops fetalis.